Everything we know about Haemanthus, the blood-testing startup from Elizabeth Holmes's partner
Billy Evans, the partner of Theranos founder Elizabeth Holmes, is currently in the process of raising money for his own startup. It's a blood-testing company.
According to reports from NPR and The New York Times, both of which spoke with anonymous sources close to the venture, 33-year-old Evans has already raised several million dollars for a new 'stealth' startup focusing on diagnostics and health testing.
Prior to this news, Evans first came into the public eye back in 2018 when he began dating Holmes, who is currently serving out an 11-year federal prison sentence for committing fraud through her infamous blood-testing company Theranos.
Over the weekend, Evans's startup Haemanthus spoke out on X to reassure investors and potential future customers that it's not 'Theranos 2.0.' The company has no apparent contact information, and the direct messages on its X account are closed. Fast Company was unable to reach the company for further comment.
Here's everything we know about the company so far.
What is Haemanthus?
Based on information provided to NPR, Haemanthus is a diagnostics company that's planning to build a tool that can scan biological material like blood, sweat, and urine to identify potential diseases. The name 'Haemanthus' itself appears to be an allusion to a flower of the same name, colloquially termed the 'blood lily.'
To many readers, that whole premise might sound strikingly similar to the story behind Theranos, which promised to dole out accurate diagnoses using a single drop of blood, before it ultimately started falling apart. However, Haemanthus took to X this Sunday to clarify that its tech is not an extension of Theranos.
The post starts by acknowledging Evans's relationship with Holmes and adding that 'Skepticism is rational,' before categorically denying any connection to Holmes's failed blood-testing company.
'This is not Theranos 2.0,' the post reads. 'Theranos attempted to miniaturize existing tests. Our approach is fundamentally different. We use light to read the complete molecular story in biological fluids, seeing patterns current tests can't detect. Not an improvement. A different paradigm.'
What kind of tech is the company developing?
Sources told NPR that Haemanthus is currently in the early stages of 'using light detection technology that can essentially guide AI sensors to conduct medical tests.'
The company is specifically focusing on Raman spectroscopy, a form of chemical analysis that's been used to diagnose amyotrophic lateral sclerosis (ALS) and some forms of cancer. Based on a notice published in late January, the company has already received a patent for its Raman spectroscopy system.
A photo provided to potential investors and obtained by The New York Times reportedly indicates that Haemanthus plans to build a small rectangular device to contain the tech, which will include a door and a digital display screen. Sources told the publication that Haemanthus plans to roll out its tech for veterinary purposes first, before ultimately developing a stamp-size, wearable device for humans.
This trajectory was confirmed in part in Haemanthus's X thread.
'We're starting with veterinary medicine. Not because it's easier, but because it's practical and meaningful. It validates our technology, helps animals who can't describe symptoms, and builds the foundation for human applications,' the post reads.
Who is working for the company?
Sources told both NPR and The New York Times that the startup currently has between 10 and 12 employees, most of whom worked with Evans previously at the lidar tech company Luminar Technologies. Haemanthus reportedly told investors that it had around two dozen advisers, including veterinarians and diagnosticians, though specific names were not provided.
How much money has been raised?
So far, The New York Times reported, the company has raised $3.5 million through family and friends and is currently seeking another $15 million from investors in the Austin and Say Francisco Bay areas. Materials reviewed by the publication reportedly suggest that the company has an ultimate goal of raising more than $50 million.
Is Elizabeth Holmes involved?
In February, Holmes told People magazine that she plans to return to her career in healthcare technology after her release, and that she's continuing to write patents for new inventions while serving her sentence.
And in its exclusive initial coverage of Haemanthus, NPR cited sources who claimed that Holmes has been providing advice to Evans on his new venture from behind bars. On X, however, Haemanthus strongly refuted that claim.
'Setting the record straight,' the company wrote. 'Elizabeth Holmes has zero involvement in Haemanthus. We've learned from her company's mistakes, but she has no role, now or future. NYT and NPR implied otherwise. We've stayed quiet to build real tech, not conceal. Demonstrating, not promising.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Vancouver company celebrating reusable food container success
started with just five stores but is now in institutions across Canada and the U.S. As Chad Pawson explains, local waste management officials say it's the type of private-sector ingenuity needed to address the region's garbage problem.
Yahoo
19 minutes ago
- Yahoo
Why Mondelez's Dividend Stands Strong in Uncertain Markets
Mondelez International, Inc. (NASDAQ:MDLZ) is one of the best dividend stocks for a bear market. Mondelez International, Inc. (NASDAQ:MDLZ) ranks among the top global snack makers and belongs to the consumer staples sector. During economic downturns, consumers typically continue buying food at consistent levels, and even tend to favor discounted options more, making large food companies like Mondelez appealing, especially when spending declines in more discretionary areas. A colourful array of products like candies, chocolates and gums on a supermarket shelf. Another reason investors are drawn to Mondelez International, Inc. (NASDAQ:MDLZ) is its strong dividend and reliable cash flow. In the latest quarter, the company generated $1.1 billion in operating cash flow and $0.8 billion in free cash flow, while returning $2.1 billion to shareholders through dividends and buybacks. Mondelez International, Inc. (NASDAQ:MDLZ) has also garnered attention on the dividend front. The company has been rewarding shareholders with growing dividends for the past 11 consecutive years. It offers a quarterly dividend of $0.47 per share and has a dividend yield of 2.83% The company has expressed confidence in its future earnings potential, which may support the strength and stability of its dividend payments. It has reaffirmed its outlook for the year, expecting organic net revenue to grow by around 5%. However, adjusted earnings per share are projected to decline by roughly 10% on a constant currency basis, mainly due to an unusual surge in cocoa prices. Despite this, the company anticipates generating over $3 billion in free cash flow for 2025. Since recessions often go hand in hand with falling stock markets, investors with shorter time horizons may find value in holding companies that offer steady or growing dividend yields. While we acknowledge the potential of MDLZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
19 minutes ago
- Yahoo
This Under-the-Radar Healthcare Stock Could Be a Solid Income Play
CVS Health Corporation (NYSE:CVS) is one of the best dividend stocks for a bear market. Even during economic downturns, people continue to rely on medications, essential consumer products, and affordable local healthcare. CVS Health Corporation (NYSE:CVS) serves as a convenient healthcare and retail destination within communities. A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. The company's overall business remains solid, thanks to its diversified operations and multiple sources of revenue. In recent years, it has expanded its presence in primary care and launched a subsidiary called Cordavis to focus on developing and marketing biosimilar drugs. Its broad reach across communities and wide range of services are key advantages. Lately, higher Medicare usage and increased post-pandemic healthcare costs have impacted the company's revenue and earnings growth. However, CVS Health Corporation (NYSE:CVS) remains profitable and maintains a solid cash position. In the most recent quarter, it reported $4.6 billion in operating cash flow. Looking ahead to 2025, the company has raised its full-year operating cash flow forecast from around $6.5 billion to approximately $7.0 billion. In addition, CVS Health Corporation (NYSE:CVS) appears to have significant room to grow its dividend. With a cash payout ratio of just 30%, even doubling that figure would still leave it within a sustainable range. Due to this strong cash generation, CVS Health Corporation (NYSE:CVS) has maintained its payouts since 1997. Currently, it offers a quarterly dividend of $0.665 per share and has a dividend yield of 3.96%, as of June 17. While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
